Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of upadacitinib versus placebo and adalimumab in rheumatoid arthritis with inadequate response to methotrexate
MOH_2017-03-05_000030Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in rheumatoid arthritis (RA) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Not reported. Started May 2016; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on MOH_2017-03-05_000030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-05_000030.